Early versus Later Anticoagulation for Stroke with Atrial Fibrillation

Urs Fischer,Masatoshi Koga,Daniel Strbian,Mattia Branca,Stefanie Abend,Sven Trelle,Maurizio Paciaroni,Götz Thomalla,Patrik Michel,Krassen Nedeltchev,Leo H. Bonati,George Ntaios,Thomas Gattringer,Else-Charlotte Sandset,Peter Kelly,Robin Lemmens,P.N. Sylaja,Diana Aguiar de Sousa,Natan M. Bornstein,Zuzana Gdovinova,Takeshi Yoshimoto,Marjaana Tiainen,Helen Thomas,Manju Krishnan,Gek C. Shim,Christoph Gumbinger,Jochen Vehoff,Liqun Zhang,Kosuke Matsuzono,Espen Kristoffersen,Philippe Desfontaines,Peter Vanacker,Angelika Alonso,Yusuke Yakushiji,Caterina Kulyk,Dimitri Hemelsoet,Sven Poli,Ana Paiva Nunes,Nicoletta Caracciolo,Peter Slade,Jelle Demeestere,Alexander Salerno,Markus Kneihsl,Timo Kahles,Daria Giudici,Kanta Tanaka,Silja Räty, Rea Hidalgo,David J. Werring,Martina Göldlin,Marcel Arnold,Cecilia Ferrari,Seraina Beyeler,Christian Fung,Bruno J. Weder,Turgut Tatlisumak,Sabine Fenzl,Beata Rezny-Kasprzak,Arsany Hakim,Georgia Salanti,Claudio Bassetti,Jan Gralla,David J. Seiffge,Thomas Horvath,Jesse Dawson

New England Journal of Medicine（2023）

引用 5|浏览58

暂无评分

摘要

In this trial, the incidence of recurrent ischemic stroke, systemic embolism, major extracranial bleeding, symptomatic intracranial hemorrhage, or vascular death at 30 days was estimated to range from 2.8 percentage points lower to 0.5 percentage points higher (based on the 95% confidence interval) with early than with later use of DOACs. (Funded by the Swiss National Science Foundation and others; ELAN ClinicalTrials.gov number, NCT03148457.).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要